StockWatch: Amid Nvidia Turmoil, What Happens to Its Life Sciences Collaborations?
This StockWatch piece from GEN looks at what the turmoil around Nvidia could mean for the company's partnerships in life sciences, with a focus on a Danish link.
Nvidia has partnered in recent years with the Novo Nordisk Foundation, the nonprofit majority owner of Novo Nordisk (Nasdaq Copenhagen: NOVO-B; NYSE: NVO), the arch-rival of Eli Lilly in obesity and diabetes drugs. In June 2025 the foundation agreed to house an Nvidia supercomputer at the Danish Centre for AI Innovation. Last month the centre announced it had invested in 32 NVIDIA DGX Rubin NVL8 systems, which gives Denmark access to the latest generation of AI infrastructure.
GEN asked Lilly, AstraZeneca and GSK whether they would review their partnerships with Nvidia. At deadline, none of their spokespeople had responded. Novo Nordisk referred GEN to the Danish Centre for AI Innovation, which also had not responded. A Thermo Fisher spokesperson confirmed receiving GEN's query but offered no comment.
On the tools side, Danaher (NYSE: DHR) agreed last month to partner with Nvidia. Danaher will combine its scientific instrumentation, automation technologies, laboratory workflow software and domain expertise with Nvidia's accelerated computing and AI technologies.
The excerpt does not spell out the nature of Nvidia's turmoil. What it shows is how many drugmakers and tool providers have tied themselves to Nvidia, including Denmark's national AI infrastructure, and that none of the companies contacted had yet said whether those ties would change.